<DOC>
	<DOC>NCT01829919</DOC>
	<brief_summary>The purpose of this study is to assess the pharmacokinetics (absorption, breakdown and elimination from the body), safety and tolerability of Brisdelle (paroxetine mesylate) Capsules 7.5 mg when given as a single dose and multiple doses.</brief_summary>
	<brief_title>Pharmacokinetic Evaluation of Brisdelle™ (Formerly Known as Mesafem) Following Single &amp; Repeat Oral Administration in Healthy Postmenopausal Women</brief_title>
	<detailed_description>This study is for research only and is not designed to treat a medical condition.</detailed_description>
	<mesh_term>Paroxetine</mesh_term>
	<criteria>Subjects who are healthy postmenopausal, nonsmoking women of any race and ≥40 years of age at screening. Subjects who have a recent history or presence of glaucoma, migraines, cardiovascular, hepatobiliary, renal, gastrointestinal, neurologic, psychiatric, dermatologic, pulmonary, cerebrovascular, endocrine, hematologic, thromboembolic, immunologic disease or any other disorder which requires physician care; subjects who have existing medical conditions which might interfere with absorption, distribution, metabolism, or excretion of study medication; history of selfinjurious behavior; history of clinical diagnosis of depression; or treatment for depression; history of clinical diagnosis of borderline personality disorder; presence of any of the following psychiatric disorders within the timeframes specified: Major Depressive DisorderLifetime; DysthymiaPast 2 Years; Bipolar DisorderLifetime; Panic DisorderLifetime; AgoraphobiaPast Month; Social PhobiaPast Month; Obsessive Compulsive DisorderPast Month; Generalized AnxietyLifetime; Psychotic DisordersLifetime; Anorexia NervosaPast 10 Years; BulimiaPast 10 Years; Suicidality/Suicide IdeationLifetime; Post Traumatic Stress DisorderLifetime. Subjects with a history of seizures; sitting blood pressure (BP) &lt; 90/50 or &gt; 150/90 mmHg; sitting heart rate (HR) &lt; 45 or &gt; 90 beats/min; clinical laboratory test results outside of the normal range for the laboratory conducting the test; positive urine pregnancy test at Screening or Day 0; subjects who have a history of sensitivity to active and/or inactive ingredients in Brisdelle (paroxetine mesylate) Capsules 7.5 mg; subjects who have a history of significant allergies; subjects who have a present or past history of narcotic addiction, drug abuse, or alcoholism; subjects who have smoked or used tobacco during the last 6 months; subjects who have donated one or more pints of blood within 30 days prior to treatment administration; subjects who have symptoms of any significant acute illnesses at the screening visit; subjects who used any investigational drug within 30 days prior to treatment administration; subjects who took any substances known to be Cytochrome P450 2D6 (CYP2D6) inhibitors within 14 days of study start and throughout the entire study; subjects who used any prescription medications within 14 days of the screening visit; subjects who used St John's Wort within 14 days of the screening visit; subjects who used any over the counter preparations including herbal or nutritional supplements and multivitamins within 10 days prior to receiving the first study treatment; subjects who have consumed foods or beverages containing caffeine/xanthine or alcohol; subjects who have a positive screen for hepatitis B surface antigen (HBsAg) or hepatitis C antibody; subjects who have a positive screen for the Human Immunodeficiency Virus (HIV) antibody; subjects who have a positive urine drug screen; subjects who have any clinically significant illness within 90 days prior to receiving the first dose of study medication.</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Menopause</keyword>
	<keyword>Hot flashes</keyword>
	<keyword>Vasomotor symptoms</keyword>
	<keyword>Climacteric symptoms</keyword>
	<keyword>perimenopause</keyword>
	<keyword>Mesafem</keyword>
	<keyword>Brisdelle</keyword>
	<keyword>Low-Dose Mesylate salt of Paroxetine (LDMP)</keyword>
</DOC>